DV Biomed Valuation

Is 6539 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6539 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6539 (NT$68.1) is trading below our estimate of fair value (NT$71.94)

Significantly Below Fair Value: 6539 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6539?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 6539. This is calculated by dividing 6539's market cap by their current preferred multiple.
What is 6539's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	NT$1.41b

6539 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	5.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6539's PE Ratio compare to its peers?

The above table shows the PE ratio for 6539 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	41.9x
3164 GenMont Biotech Incorporation	27.9x	n/a	NT$2.0b
4186 Taiwan Advance Bio-Pharmaceutical	68.3x	n/a	NT$1.5b
1780 Allied Biotech	15.5x	n/a	NT$1.6b
4160 Genetics Generation Advancement	56x	n/a	NT$2.5b
6539 DV Biomed	26.7x	n/a	NT$1.4b

Price-To-Earnings vs Peers: 6539 is good value based on its Price-To-Earnings Ratio (26.7x) compared to the peer average (41.9x).

Price to Earnings Ratio vs Industry

How does 6539's PE Ratio compare vs other companies in the Asian Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	45.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	45.0%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 6539 is good value based on its Price-To-Earnings Ratio (26.7x) compared to the Asian Biotechs industry average (32.4x).

Price to Earnings Ratio vs Fair Ratio

What is 6539's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6539 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6539's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.